About Tissue factor pathway inhibitor
Tissue factor pathway inhibitor (TFPI) is a protein
from Homo sapiens identified by UniProt accession
P10646, 304 residues long.
MolForge cross-references it against 0 known binders and
432 disease associations.
Target properties
| Protein name | Tissue factor pathway inhibitor |
|---|
| UniProt accession | P10646 |
|---|
| Gene | TFPI |
|---|
| Organism | Homo sapiens |
|---|
| Length | 304 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (432)
Diseases linked to this target (Open Targets).
- hemophilia A · score 0.39
- hemophilia B · score 0.38
- drug toxicity · score 0.37
- intracranial hemorrhage · score 0.37
- neurodegenerative disease · score 0.37
- age at menopause · score 0.32
- multiple sclerosis · score 0.32
- Parkinson disease · score 0.32
- lysosomal storage disease · score 0.32
- Alzheimer disease · score 0.32
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P10646-F1 | alphafold | PREDICTED | 73.66 | — |
Amino-acid sequence (304 residues)
MIYTMKKVHA LWASVCLLLN LAPAPLNADS EEDEEHTIIT DTELPPLKLM HSFCAFKADD GPCKAIMKRF FFNIFTRQCE EFIYGGCEGN QNRFESLEEC KKMCTRDNAN RIIKTTLQQE KPDFCFLEED PGICRGYITR YFYNNQTKQC ERFKYGGCLG NMNNFETLEE CKNICEDGPN GFQVDNYGTQ LNAVNNSLTP QSTKVPSLFE FHGPSWCLTP ADRGLCRANE NRFYYNSVIG KCRPFKYSGC GGNENNFTSK QECLRACKKG FIQRISKGGL IKTKRKRKKQ RVKIAYEEIF VKNM
Explore Tissue factor pathway inhibitor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets